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Previewsglucose metabolism through the PPP to
purine synthesis. Mitsuishi et al. (2012)
therefore argue that a proliferative signal
provided by the PI3K-Akt pathway is
required to increase flux through the
PPP in an Nrf2-dependent fashion and
provide evidence that Akt is activated
in mouse forestomach. The idea that
increased PI3K-Akt signaling in the liver
allows Nrf2 to induce G6pd, Tkt, Taldo1,
Pgd, and Me1 was confirmed by making
liver-specific Pten and Keap1 double-
knockout mice.
In summary, Mitsuishi et al. show that
under the direction of PI3K-Akt signaling,
Nrf2 regulates the expression of genes
involved in the PPP, generation of NADPH,
and synthesis of purine nucleotides. They
have expanded our knowledge of Nrf2
functions from increasing cytoprotection
to the regulation of metabolism and the
synthesis of macromolecules, thereby
providing an explanation of how Nrf2
supports cell proliferation. A number of
critical issues remain unresolved. The
mechanism by which Nrf2-mediated
induction of metabolic genes requires
both inhibition of Keap1 and activation of
PI3K-Akt, as opposed to induction of anti-
oxidant and detoxication genes, whichrequires only inhibition of Keap1, is
unclear. It is also not known how Nrf2
cooperateswith other transcription factors
implicated in metabolic reprogramming in
tumor cells, including p53, Myc, and
HIF1a (Kroemer and Pouyssegur, 2008;
Ward and Thompson, 2012), to maintain
high rates of glycolysis and increase cell
proliferation. It remains to be established
whether activation of Nrf2 along with the
PI3K-Akt pathway is sufficient to promote
carcinogenesis. Lastly, while inhibition of
Nrf2 as a cancer chemotherapeutic
strategy is an attractive proposition, it
may be unwise to reduce PPP metabolic
flux, given that the pathway provides an
important defense for neurons and astro-
cytes against oxidative damage and
neuronal death (Fernandez-Fernandez
et al., 2012). Accordingly, it is becoming
clear that Nrf2, in combination with growth
factorsignaling,providesacritical interface
between oxidative stress sensing and
metabolic reprogramming of cells.
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The mitochondrial pyruvate carrier (MPC) is essential for several major pathways of carbohydrate, fat, and
amino acidmetabolism, yet its molecular identity has remained elusive. Two recent papers in Science (Herzig
et al., 2012; Bricker et al., 2012) implicate three newly identified inner mitochondrial membrane proteins as
MPC components.Pyruvate lies at the heart of carbohydrate,
fat, and amino acid metabolism and is
usually produced in the cytoplasm before
being transported into the mitochondria
for further metabolism (Figure 1). Trans-
port is mediated by the mitochondrial
pyruvate carrier (MPC) whose existencewas confirmed in 1974 by the discovery of
a potent and specific inhibitor, a-cyano-4-
hydroxycinnamate (CHC). Subsequently,
its substrate and inhibitor specificity and
roles in metabolism were extensively in-
vestigated (Halestrap et al., 1980). Trans-
port of most metabolites across the innermitochondrial membrane (IMM) involves
members of the mitochondrial carrier
family (MCF; 53 members in humans),
which are usually 30–35 kDa in size
and have six transmembrane domains
(TMDs) (Palmieri and Pierri, 2010). In
1981 the CHC analog UK5099 (Ki 5 nM)6, August 8, 2012 ª2012 Elsevier Inc. 141
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Figure 1. Major Pathways of Mammalian Carbohydrate, Fat, and Amino Acid Metabolism
that Require the MPC
Pathways are color coded as indicated. The dotted green line represents the indirect pathway of oxaloac-
etate transport out of the mitochondria. Note that the MPC is also used for the transport of the ketone
body, acetoacetate, and is known to be inhibited by phenylpyruvate and a-ketoisocaproate. These mono-
carboxylates accumulate in phenylketonuria and maple syrup urine disease, respectively, and may
account for the perturbation of brain energy metabolism and development associated with these diseases
(Halestrap et al., 1980).
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Previewswas shown to protect a 15 kDa inner
mitochondrial membrane (IMM) protein
from labeling with [3H]-N-phenylmalei-
mide (Thomas and Halestrap, 1981) but
the molecular identity of the labeled
protein was not established. Another
attempt to identify the MPC involved
measuring pyruvate transport into mito-
chondria from strains of yeast (Saccharo-
myces cerevisiae) in which each member
of the MCF without an ascribed func-
tion had been deleted. Only in the case
of YIL006w was inhibitor-sensitive pyru-
vate transport totally abolished, imply-
ing that this gene encoded the MPC
(Hildyard and Halestrap, 2003), although
Palmieri’s group subsequently reported
that YIL006w encoded the mitochondrial
NAD+ transporter (Todisco et al., 2006).
Thus, after nearly 40 years, the identity
of the MPC remains a mystery—but two
recent papers in Science (Herzig et al.,
2012; Bricker et al., 2012) may have
changed this.
Herzig et al. (2012) deleted yeast genes
encoding the three members of a family
of IMM proteins of unknown function
that are predicted to contain three TMDs142 Cell Metabolism 16, August 8, 2012 ª201and are conserved from yeast to man.
Deletion of these genes impaired mito-
chondrial lipoic acid production from
pyruvate but not from valine or leucine.
Lipoic acid is synthesized frommitochon-
drial acetyl-CoA, itself produced from
pyruvate by oxidative decarboxylation
catalyzed by pyruvate dehydrogenase
(PDH). Indeeddeletion of PDHproduced a
similar phenotype, yet PDH activity was
normal in leucine- or valine-treated cells
where lipoic acid is synthesized indepen-
dently of PDH. This led the authors to
conclude that this protein family was
required for pyruvate transport into mito-
chondria. They named the gene products
Mpc1, Mpc2, and Mpc3, and substan-
tiated their role by measurement of
UK5099-inhibitable [14C]-pyruvate uptake
into isolated mitochondria from the dif-
ferent yeast strains. The mouse genome
contains two orthologs, mMpc1 and
mMpc2, and their expression rescues
the yeast deletion mutants. Final confir-
mation that mMpc1 and mMpc2 facilitate
pyruvate transport was provided by ex-
pressing them in Lactococcus lactis and
demonstrating UK5099-sensitive pyru-2 Elsevier Inc.vate uptake only when both were ex-
pressed together. The authors conclude
that mMpc1 and mMpc2 are essential
components of the MPC in mammalian
mitochondria.
Bricker et al. (2012) reached a similar
conclusion. The growth media require-
ments and metabolomic analysis of yeast
Mpc1 and Mpc2 deletions implicated
these proteins in mitochondrial pyruvate
transport, and the authors substantiated
this role by assaying UK5099-inhibitable
[14C]-pyruvate uptake into mitochondria.
Themetabolic requirements ofDrosophila
melanogaster lacking orthologs of Mpc1
and Mpc2 were consistent with these
proteins playing the same role in fly mito-
chondria. In addition, knockdown of the
mammalian orthologs in cultured mouse
embryonic fibroblasts inhibited pyruvate-
dependent respiration. Furthermore, in
three unrelated families, children with
lactic acidosis and hyperpyruvatemia
showed mutations in a conserved region
of human Mpc1, while their fibroblasts
exhibited impaired pyruvate-dependent
respiration that was restored by expres-
sion of wild-type Mpc1.
Together, these two papers demon-
strate that Mpc1 and Mpc2 play a critical
role inmammalian mitochondrial pyruvate
metabolism, but do they mediate trans-
port? Mitochondrial pyruvate transport
is very fast and occurs on top of a signifi-
cant rate of inhibitor-insensitive free diffu-
sion. In addition, pyruvate is metabolized
rapidly within the mitochondria. For this
reason, accurate measurement of pyru-
vate transport requires the use of low
temperatures, inhibition of metabolism,
and rapid termination of transport by
centrifugation (Halestrap et al., 1980).
Given the technical challenges in mea-
suring pyruvate transport, it remains
possible that the [14C]-pyruvate uptake
measured in these two papers actually
represents pyruvate metabolism rather
than transport. Indeed, Herzig et al.
(2012) showed that PDH activity was
reduced in mitochondria from the Mpc
mutants due to the decreased mito-
chondrial lipoamide, and this would be
expected to reduce accumulation of
pyruvate metabolites. Furthermore, the
MPC inhibitor UK5099, at the very high
concentration used by the authors, may
also inhibit mitochondrial respiration.
The most convincing data is undoubtedly
that demonstrating increased pyruvate
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Previewsuptake into Lactococcus lactis expressing
mMpc1 and mMpc2, although the rates
measured were very slow.
Despite these caveats, it is likely that
Mpc1 and Mpc2 do represent compo-
nents of the MPC. Indeed, this might ex-
plain the earlier identification of a 15 kDa
protein as the binding site for UK5099 in
rat heart and liver IMMs (Thomas and
Halestrap, 1981). Interestingly, this inhib-
itor is known to attack a critical thiol group
on the MPC and there is a conserved
cysteine in TMD3 of Mpc1 but not Mpc2.
The authors suggest that with only three
TMDs, the Mpc members are most likely
to form an active transporter by associ-
ating in a multisubunit complex, and both
papers present coimmunoprecipitation
data in support of this notion. Equally
possible is that there is a member of the
MCF family that interacts with Mpc1 and
Mpc2 to mediate mitochondrial pyruvate
transport. This would be consistent with
blue native-polyacrylamide gel electro-
phoresis data that suggest the Mpc1 andMpc2 exist as part of a 150 kDa complex
(Bricker et al., 2012). Interestingly, the
plasma membrane transport of pyruvate
and lactate is mediated by a 12-trans-
membrane protein that requires a single
transmembrane ancillary protein (Hale-
strap, 2012). Future work will be needed
to clarify which, if any, of these explana-
tions is correct, and ultimate proof will
require measurement of pyruvate trans-
port by the purified protein(s) reconsti-
tuted into proteoliposomes. It will also be
important to establish whether the MPC
is regulated in response to known
changes in pyruvate metabolism such as
in the starved-to-fed transition and during
exercise and whether this regulation is
transcriptional or by covalent modifica-
tion. Another interesting area to explore
is whether MPC expression is reduced in
tumor cells whose energy metabolism is
largely glycolytic.
In conclusion, the data of Herzig et al.
(2012) and Bricker et al. (2012) may not
provide a complete picture of the identityCell Metabolism 1of the MPC, but they do represent a major
step forward and provide a much-needed
stimulus for future work on its roles and
regulation.
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